company background image
CRXT.Q logo

Clarus Therapeutics Holdings OTCPK:CRXT.Q Stock Report

Last Price

US$0.0011

Market Cap

US$57.2k

7D

0%

1Y

-99.9%

Updated

10 Feb, 2023

Data

Company Financials +

Clarus Therapeutics Holdings, Inc.

OTCPK:CRXT.Q Stock Report

Market Cap: US$57.2k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

CRXT.Q Stock Overview

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States.

CRXT.Q fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Clarus Therapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clarus Therapeutics Holdings
Historical stock prices
Current Share PriceUS$0.0011
52 Week HighUS$3.94
52 Week LowUS$0.001
Beta0
1 Month Change-92.81%
3 Month Change-94.63%
1 Year Change-99.92%
3 Year Changen/a
5 Year Changen/a
Change since IPO-99.99%

Recent News & Updates

Recent updates

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Aug 18

Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies

Dec 01

Shareholder Returns

CRXT.QUS PharmaceuticalsUS Market
7D0%0.2%1.3%
1Y-99.9%23.1%29.8%

Return vs Industry: CRXT.Q underperformed the US Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: CRXT.Q underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is CRXT.Q's price volatile compared to industry and market?
CRXT.Q volatility
CRXT.Q Average Weekly Movement47.7%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: CRXT.Q's share price has been volatile over the past 3 months.

Volatility Over Time: CRXT.Q's weekly volatility has increased from 35% to 48% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200316n/ahttps://clarustherapeutics.com

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Clarus Therapeutics Holdings, Inc. Fundamentals Summary

How do Clarus Therapeutics Holdings's earnings and revenue compare to its market cap?
CRXT.Q fundamental statistics
Market capUS$57.22k
Earnings (TTM)-US$24.49m
Revenue (TTM)US$16.91m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRXT.Q income statement (TTM)
RevenueUS$16.91m
Cost of RevenueUS$3.62m
Gross ProfitUS$13.29m
Other ExpensesUS$37.77m
Earnings-US$24.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin78.58%
Net Profit Margin-144.82%
Debt/Equity Ratio-310.1%

How did CRXT.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.